Cancer Causes Control:进行局部前列腺癌雄激素阻断治疗糖尿病患者的糖尿病并发症风险研究

2018-07-02 AlexYang MedSci原创

雄激素阻断治疗(ADT)在局部前列腺癌治疗中使用逐渐增加,且与随后的长期副作用结果相关,包括糖尿病。虽然之前的研究表明了ADT能够在糖尿病患者中对血糖控制起不良作用,但它与糖尿病并发症之间的相关性还没有调查过。最近,有研究人员调查了ADT治疗与前列腺癌患者糖尿病并发症之间的相关性。研究是一个回顾性的群体研究,并且在新诊断为局部前列腺癌患者中进行,时间为1995年到2008年之间。研究群体为经历根治

雄激素阻断治疗(ADT)在局部前列腺癌治疗中使用逐渐增加,且与随后的长期副作用结果相关,包括糖尿病。虽然之前的研究表明了ADT能够在糖尿病患者中对血糖控制起不良作用,但它与糖尿病并发症之间的相关性还没有调查过。最近,有研究人员调查了ADT治疗与前列腺癌患者糖尿病并发症之间的相关性。

研究是一个回顾性的群体研究,并且在新诊断为局部前列腺癌患者中进行,时间为1995年到2008年之间。研究群体为经历根治性前列腺癌切除或者放射治疗且存在2型糖尿病(T2DM)的男性,并且跟踪调查到2010年12月(n=5336)。研究人员还利用风险比例模型调查了前列腺癌诊断后,ADT的使用与糖尿病并发症、个体并发症(糖尿病神经病变、糖尿病视网膜病变、糖尿病截肢或糖尿病性白内障)之间的相关性。研究发现,前列腺癌诊断后,ADT的使用与所有糖尿病并发症风险的增加相关(调整后风险比,AHR, 1.12, 95% CI 1.03-1.23),并且与个体并发症风险的增加同样相关。

最后,研究人员指出,在那些接受前列腺癌治疗意向疗法的T2DM男性患者中使用ADT是与糖尿病并发症风险的增加相关的。他们的发现支持了ADT能够恶化糖尿病控制的结论。另外,研究人员也指出,还需要更多的研究来确定这些结果,从而为ADT的是否使用进行科学的判断。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
    2018-09-09 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
    2018-07-04 一个字-牛

    学习了谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
    2018-07-04 chg122
  9. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1710150, encodeId=e9661e1015054, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Nov 12 11:23:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055634, encodeId=556b2055634ed, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Feb 05 16:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758004, encodeId=1dac1e58004d1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 09 02:23:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641272, encodeId=c56116412e2f9, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Mon Sep 24 23:23:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046239, encodeId=705d20462395e, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 14 17:23:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329221, encodeId=9ec332922173, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Jul 04 11:32:15 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385157, encodeId=61ee138515ec7, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405844, encodeId=c30c140584443, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413035, encodeId=e2491413035b3, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474532, encodeId=e11f14e4532ab, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 04 11:23:00 CST 2018, time=2018-07-04, status=1, ipAttribution=)]

相关资讯

JAMA:男性前列腺癌筛查也有危害?看推荐更新怎么说

发表在《JAMA》的一项由美国学者进行的评价,对2012年美国预防服务工作组(USPSTF)关于基于特定前列腺抗原(PSA)筛查前列腺癌的推荐进行了更新。

BJU Int:重复活检前列腺癌男性中,急性和慢性炎症均与更低的嗜神经侵袭相关

最近,有研究人员评估了急性和慢性炎症与嗜神经侵袭(PNI)在前列腺癌活检阳性中的相关性。研究包括了1399个前列腺癌患者的前列腺活检阳性样本,并利用卡方检验和克鲁斯卡尔-沃利斯检验以及逻辑回归等统计学方法评估了急性和慢性炎症与PNI之间的的相关性,并且调整了临床病理和生化变量。研究发现,PNI在133例(9.5%)活检中鉴定到。267例(19.1%)活检具有急性炎症,1038例(74.2%)具有慢

Int J Biol Macromol:DCTPP1过表达诱导的自噬能够促进肿瘤恶化和预测前列腺癌不良临床治疗结果

尽管dCTP焦磷酸酶1(DCTPP1)已经被报道在各种癌症中与不良临床治疗结果相关,但是否他在前列腺癌(PCa)中具有重要作用仍旧不清楚。最近,有研究人员利用免疫组化试验展示了DCTPP1蛋白表达水平在PCa组织中比非癌组织中显著更高。更多的是,与低格林森得分患者相比,高格林森得分患者的DCTPP1蛋白水平和mRNA水平在PCa组织中均上调。癌症基因组数据库RNA-seq数据分析表明DCTPP1的

Nature:癌症免疫疗法新发现:阻断一种蛋白,让肿瘤明显缩小

免疫疗法在许多癌症类型中显示出很大的希望,但迄今为止,它们在前列腺癌中的作用仅限于一小部分男性。这项新研究发现了一种全新的方法来修改免疫系统以对抗前列腺癌。

Sophiris Bio披露了前列腺癌II期研究中的死亡事件

近日,Sophiris Bio透露,在正在进行的实验性前列腺癌药物topsalysin IIb期临床试验中的一例患者死亡事件,该患者在第二次给药后当天死亡。该公司表示,目前正在调查原因,并且作为预防措施,没有其他患者将接受第二次给药。

Oncogene:MacroH2A1.2能够抑制前列腺癌诱导的破骨细胞的形成

破骨细胞是多核的具有骨再吸收活性的细胞,并且分化自造血干细胞。前列腺癌细胞能够频繁的扩展到骨组织并且分泌可溶性的信号分子来刺激破骨细胞的分化和骨质吸收。然而,前列腺癌细胞分泌的破骨细胞形成的可溶性因子的表达过程及机制仍旧不清楚。MacroH2A1.2(mH2A)是一个组蛋白变体,在特定的基因组位点能够替代H2A,并且能够建立具有功能性差异的染色质区域。最近,有研究人员报道了 mH2A1.2,一种m